Particularly, cadonilimab offers new therapeutic opportunities in traditionally immunotherapy-resistant populations (e.g., HER2-positive, STK11-mutated, and microsatellite stable gastric cancer). This evidence concerns the gene ERBB2 and gastric cancer.